About
Pressroom
Resources
Get Updates
Issues
Access to Medicines
Funding the Fight
Health Justice
Transparency & Accountability
PEPFAR Watch
Blog
Our Impact
Take Action
Do something now
DONATE
Pharma Greed
Access to Medicines
Time to Walk Away from the WTO Proposed Text
Access to Medicines
Merck’s Molnupiravir – Overcoming impending barriers to affordable global access
Access to Medicines
Pfizer and BioNTech Profiteering Exposed – More than Enough is Enough
Access to Medicines
New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency
Access to Medicines
Generic Licensing: the Only Path Through the Maze of Gilead and U.S. Patents that Achieves Access to Affordabl...
Access to Medicines
The President’s Trumpeteering on Drug Prices is Really a Toy Whistle
Access to Medicines
Drug Companies Getting Away with Murder – Trump’s Solution: Round Up Foreign Country Targets
Access to Medicines
Lies, Distortions, and False Promises: The U.S. Position on Compulsory Licenses in the 2018 Special 301 Report
Access to Medicines
Don’t Be Afraid of Compulsory Licenses Despite US Threats: Special 301 Reports 1998-2017 – Listing Concern...
Access to Medicines
Canada Blinks in Face of US/Pharma Pressure – Supreme Court Adopts Wink-Wink Patent Utility Rule
Access to Medicines
Trump’s Draft Executive Order on Pharmaceutical Pricing: Dangerous Medicine for Consumers at Home and Abroad
Access to Medicines
Trump’s Drug Pricing Executive Order is Likely to be an Unfettered Giveaway to Big Pharma: Insights from 201...
Access to Medicines
How activists transformed the TPP from a done-deal to dead-on-arrival
Access to Medicines
Durban Reflections #1: The Threat of Big Pharma’s Monopoly Unbound
Access to Medicines
U.S.’s Newest IP Gunship Diplomacy in Colombia – Same Threats with Dollars not Bullets
SEE MORE
